Additionally, the 36-month beta value for AKBA is 0.84. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for AKBA is 251.57M and currently, short sellers hold a 7.97% ratio of that float. The average trading volume of AKBA on June 24, 2025 was 5.09M shares.
AKBA) stock’s latest price update
Akebia Therapeutics Inc (NASDAQ: AKBA) has seen a rise in its stock price by 5298855 in relation to its previous close of 3.68. However, the company has experienced a 2.25% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-04 that Akebia continues to publish important, clinically relevant data to further physicians’ understanding of Vafseo® (vadadustat) Akebia continues to publish important, clinically relevant data to further physicians’ understanding of Vafseo® (vadadustat)
AKBA’s Market Performance
Akebia Therapeutics Inc (AKBA) has seen a 2.25% rise in stock performance for the week, with a 29.54% gain in the past month and a 70.89% surge in the past quarter. The volatility ratio for the week is 2.55%, and the volatility levels for the past 30 days are at 3.99% for AKBA. The simple moving average for the last 20 days is 5.26% for AKBA stock, with a simple moving average of 76.80% for the last 200 days.
Analysts’ Opinion of AKBA
Many brokerage firms have already submitted their reports for AKBA stocks, with H.C. Wainwright repeating the rating for AKBA by listing it as a “Buy.” The predicted price for AKBA in the upcoming period, according to H.C. Wainwright is $8 based on the research report published on June 04, 2025 of the current year 2025.
Leerink Partners, on the other hand, stated in their research note that they expect to see AKBA reach a price target of $7. The rating they have provided for AKBA stocks is “Outperform” according to the report published on April 28th, 2025.
Jefferies gave a rating of “Buy” to AKBA, setting the target price at $6 in the report published on April 01st of the current year.
AKBA Trading at 30.62% from the 50-Day Moving Average
After a stumble in the market that brought AKBA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -10.69% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AKBA starting from Malabre Richard C, who sale 15,000 shares at the price of $4.01 back on Jun 09 ’25. After this action, Malabre Richard C now owns 266,914 shares of Akebia Therapeutics Inc, valued at $60,150 using the latest closing price.
Malabre Richard C, the SVP, Chief Accounting Officer of Akebia Therapeutics Inc, sale 13,334 shares at $3.53 during a trade that took place back on Jun 04 ’25, which means that Malabre Richard C is holding 266,914 shares at $47,069 based on the most recent closing price.
Stock Fundamentals for AKBA
Current profitability levels for the company are sitting at:
- -0.12 for the present operating margin
- 0.68 for the gross margin
The net margin for Akebia Therapeutics Inc stands at -0.25. The total capital return value is set at -0.1.
Based on Akebia Therapeutics Inc (AKBA), the company’s capital structure generated 0.69 points at debt to capital in total, while cash flow to debt ratio is standing at -0.64. The debt to equity ratio resting at 2.2. The interest coverage ratio of the stock is -2.78.
Currently, EBITDA for the company is -13.72 million with net debt to EBITDA at -10.03. When we switch over and look at the enterprise to sales, we see a ratio of 4.85. The receivables turnover for the company is 3.0for trailing twelve months and the total asset turnover is 0.6. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.23.
Conclusion
In conclusion, Akebia Therapeutics Inc (AKBA) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
